By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:







CEO: Ian T. Clark

CEO: Ed Harrington

Chief Medical Officer: Sandra J. Horning, MD

Chief Compliance Officer: Frederick C. Kentz, III


Please click here for clinical trial information.

Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY) Release: Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared To Bendamustine Plus Rituxan 9/19/2017 7:26:29 AM
Amgen (AMGN), Allergan (AGN) Make History With First Cancer Biosimilar OK—Will Take on Genentech (RHHBY)'s $6 Billion Best-Seller 9/15/2017 5:40:14 AM
Why 23andMe Quietly Recruited Genentech (RHHBY) Scientists 9/12/2017 9:22:08 AM
Clarus Appoints Former Genentech (RHHBY) CEO Ian Clark As Operating Partner 9/11/2017 8:32:55 AM
Genentech (RHHBY)'s Macular Degeneration Candidate Flunks Phase III Study 9/8/2017 9:44:54 AM
Genentech (RHHBY) Recalls Lots Of Activase Due To Cracked And Leaking Vials 9/8/2017 6:39:51 AM
FDA Approves Genentech (RHHBY)’s Actemra (Tocilizumab) For The Treatment Of CAR T Cell-Induced Cytokine Release Syndrome 8/30/2017 10:58:18 AM
Genentech (RHHBY) Gains Priority Review For Another Drug, This Time For Lymphoma 8/28/2017 6:14:08 AM
Genentech (RHHBY)'s Hemophilia Contender Wins Priority Review From The FDA 8/24/2017 6:25:36 AM
Novogen (NVGN) Release: GDC-0084 Progress Update: On Track For Phase II Commencement In 2017 8/22/2017 7:10:56 AM